These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 8893066)

  • 21. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
    Scorpiglione N; Belfiglio M; Carinci F; Cavaliere D; De Curtis A; Franciosi M; Mari E; Sacco M; Tognoni G; Nicolucci A
    Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide YY in diabetics treated chronically with an intestinal glucosidase inhibitor.
    Füessl HS; Adrian TE; Uttenthal LO; Bloom SR
    Klin Wochenschr; 1988 Oct; 66(19):985-9. PubMed ID: 3054280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who should benefit from the use of alpha-glucosidase inhibitors?
    Godbout A; Chiasson JL
    Curr Diab Rep; 2007 Oct; 7(5):333-9. PubMed ID: 18173965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
    Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
    Clissold SP; Edwards C
    Drugs; 1988 Mar; 35(3):214-43. PubMed ID: 3286212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
    Leonhardt W; Hanefeld M; Fischer S; Schulze J
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():45-9. PubMed ID: 8001628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
    Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
    Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
    Dimitriadis GD; Tessari P; Go VL; Gerich JE
    Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
    Welborn TA
    Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
    Holman RR; Cull CA; Turner RC
    Diabetes Care; 1999 Jun; 22(6):960-4. PubMed ID: 10372249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
    Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
    Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined therapy with insulin and alpha-glucosidase inhibitor].
    Watanabe K; Kawamori R
    Nihon Rinsho; 1997 Nov; 55 Suppl():261-6. PubMed ID: 9434478
    [No Abstract]   [Full Text] [Related]  

  • 37. Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months.
    Gérard J; Luyckx AS; Lefebvre PJ
    Diabetologia; 1981 Nov; 21(5):446-51. PubMed ID: 7028558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
    Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T
    Acta Diabetol; 1998 Apr; 35(1):34-40. PubMed ID: 9625287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of acarbose in the prevention and treatment of hypoglycaemia.
    Lefebvre PJ; Scheen AJ
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():40-4. PubMed ID: 8001627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance.
    Kentrup H; Bongers H; Spengler M; Kusenbach G; Skopnik H
    Eur J Pediatr; 1999 Jun; 158(6):455-9. PubMed ID: 10378391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.